Full-Time

Senior Portfolio Accounting Analyst

Portfolio Accounting

Posted on 1/31/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$80k - $180k/yr

+ Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA

In Person

Category
Accounting (1)
Required Skills
Fixed Income Securities
Requirements
  • A college degree and a minimum of 5-7 years of experience in the financial services industry with some experience working in portfolio or fund accounting
  • In depth knowledge of investment operations including but not limited to: trade settlement; IBOR versus ABOR; fixed income and equity life cycle events; reconciliation; performance reporting
  • A proven track record of developing, maintaining, and enhancing workflows/controls with understanding of potential impact of workflows on other areas of the firm
  • Must be well organized, resourceful, and motivated
  • Able to adjust to rapidly changing priorities
  • Working knowledge of generally accepted accounting principles
  • Extensive experience with fund accounting systems; preferably Advent Geneva
  • Experience working with, and accounting for, derivatives and synthetic exposures
  • Proven track record of initiating and managing change utilizing strong business judgment, risk analysis skills and risk mitigation techniques
  • Broad knowledge of capital markets
  • Well-developed interpersonal and presentation skills, both verbal and written
  • High degree of integrity and professionalism
Responsibilities
  • Provide expertise on current accounting standards
  • Central point of contact for inquiries related to accounting and applications utilizing accounting data: IBOR, performance, client guidelines, trade settlement, reconciliation, front end tools
  • Oversee all daily, monthly, quarterly, and annual controls to ensure consistent and accurate accounting data
  • Strategically review our accounting capabilities and make recommendations on areas where we need additional development
  • Provide leadership and education across the firm regarding our accounting capabilities and work to resolve accounting issues experienced by cross-functional users of the data
  • Perform impact analysis of regulatory and operational changes in portfolio accounting that impact the investment process and suggest ways to address changes, both tactically and strategically
  • Provide guidance and expertise to Business Analysts and IT regarding development requirements for accounting initiatives
Desired Qualifications
  • Work towards CPA, advanced degree, or CFA is a plus
  • Extensive experience with fund accounting systems; preferably Advent Geneva
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60.2B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • Hartford Funds adds advisor distribution and deepens U.S. wealth reach.
  • Liquid alternatives expansion can capture demand for market-neutral strategies in volatile markets.
  • Sustainable investing and climate-aware portfolios can win mandates from institutions.

What critics are saying

  • Hartford integration faces regulatory delays and execution risk until Q1 2027.
  • Fee compression threatens revenue as institutions pressure pricing on large mandates.
  • Sustained underperformance would trigger redemptions, talent departures, and severe brand damage.

What makes Wellington Management unique

  • Independent private partnership since 1928, with nearly 50 investment teams.
  • Combines research, trading, data science, and client service across asset classes.
  • Manages $1.3 trillion through globally integrated, boutique-style investment approaches.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Wellington Management who can refer or advise you

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE